Projects Don't End at Closeout: Why Benefits Realization is the True Measure of Success in Biotech and Pharma
- Jordan Webb
- Feb 19
- 6 min read
Updated: Mar 5
Introduction
The instinct in project management is to celebrate when the project closes — deliverables handed off, resources released, final report filed. But in biotech and pharma, like most industries, the real question isn't "did we finish?" — it's "did it matter?". Projects are investments. Every project begins with a business case that outlines expected costs, benefits, and value creation — yet most organizations lack a post-closure framework to actually verify that value was delivered. The Project Management Body of Knowledge (PMBOK) Guide is explicit: the Close Project or Phase process must confirm "the extent to which value or the capability to deliver value has been achieved" — not just that work is done. This blog explores the concept of project "tails" — the post-closure period where real ROI is measured — and how life sciences organizations can build the KPI and process infrastructure to track it.
The Business Case Sets the Promise — Post-Project Tracking Must Honor It
Every biotech/pharma project starts as a business case: a documented economic feasibility study outlining costs, expected benefits, and strategic alignment. That business case is essentially a contract with the organization — "invest here, and here's what you'll get." The problem: once the project closes, the team disbands, budgets close out, and nobody formally owns the question of whether those promised benefits actually arrived. Benefits realization management (BRM) is the discipline that bridges this gap — tracking whether the investment paid off after the dust settles. In pharma, the stakes are especially high: Deloitte's 15-year study of pharma R&D showed an average internal rate of return (IRR) of 5.9% in 2024 after years of decline (link), underscoring that the industry cannot afford to invest without knowing potential return.
What Is Benefits Realization Management (BRM)?
BRM is the structured process of identifying, planning, tracking, and sustaining the value a project is supposed to generate — before, during, and after project completion. Key distinction: BRM is not about tracking project outputs (did we deliver the report, the IND filing, the SOPs?) — it's about tracking outcomes (did the output produce the intended value?). The Project Management Institute lists the Benefits Management Plan as a core business document input to the Close Project process, alongside the business case — it should define what benefits are expected and how they'll be measured.
BRM requires three things established early:
Clearly defined benefits tied back to the original business case
Designated benefit owners who remain accountable post-closure
Pre-agreed KPIs and measurement timelines that extend beyond the project close date
A Benefits Realization Plan (BRP) should include benefit identification, benefit ownership, key performance indicators (KPIs), a timeline for when each benefit is expected to materialize, and risk mitigation strategies for threats to benefit delivery
Critical point: these elements must be defined at initiation, not retroactively after closeout
Why This Matters Especially in Life Sciences
Drug development projects are among the most capital-intensive investments in any industry — the average R&D cost per asset was $2.23 billion in 2024 (link). Each stage of development (discovery, IND-enabling, Phase I/II/III, NDA/BLA submission) is often treated as a standalone project or project phase — but each one feeds a larger value chain where the ROI isn't realized until commercialization, sometimes years later. Common examples of project "tails" in biotech/pharma where BRM is essential:
A Phase II trial project closes — but the benefits (pipeline progression, partnership readiness, regulatory credibility) are only visible 12–24 months later
A manufacturing process improvement project closes — but cost savings and yield improvements are realized over subsequent production cycles
A regulatory submission project closes — but the benefit (approval, label breadth, market access) arrives months post-submission
A data management/software implementation project closes — but operational efficiency gains emerge over the following fiscal year
Many projects lack a strong focus on benefits realization after completion — often, the project team moves on to other tasks without ensuring that the value continues to be delivered. In a portfolio context, failing to measure post-project benefits means organizations cannot accurately compare the ROI of different investments, making future portfolio decisions weaker
KPIs to Define Early — Organized by Project Type in Biotech/Pharma
The key principle: KPIs for benefits realization are not the same as project execution KPIs. Execution KPIs measure whether the project ran on time and on budget. Benefits KPIs measure whether the investment generated the expected return.
R&D / Preclinical Projects
Pipeline progression rate (did the asset advance to the next phase as expected?)
Time-to-IND relative to business case projection
Attrition cost avoided (did the work de-risk the asset and prevent downstream failures?)
Clinical Trial Projects
Clinical trial success rate at primary endpoint
Patient recruitment efficiency vs. projected cost/timeline
Time from trial close to data package readiness
Number and severity of protocol deviations (quality benefit indicator)
Regulatory Projects (IND, NDA, BLA, MAA)
Approval success rate for submitted applications
Time to regulatory decision from submission
Audit findings and corrective action cycle time — tracking severity of issues identified in regulatory audits and time to resolution
Label outcome vs. target label (did you get the indication/population you sought?)
Manufacturing / Process Improvement Projects
Right-first-time (RFT) production rate post-implementation
Batch yield improvement vs. pre-project baseline
Cost-per-batch reduction vs. business case projection
Overall Equipment Effectiveness (OEE) delta
Technology / Data System Implementation Projects
Data integrity compliance rate
Operational cycle time reduction
User adoption rate and system utilization metrics
ROI measured against projected efficiency gains at 6, 12, 24 months
Commercial Launch-Enabling Projects
Market penetration rate — percentage of the target market adopting the drug within a specified timeframe
Average reimbursement/formulary coverage rate
Revenue ramp vs. business case forecast
Net Promoter Score (NPS) or patient/physician satisfaction metrics
The Process Infrastructure — What Needs to Be in Place
Benefits register — a living document created at initiation that catalogs every expected benefit, its owner, its measurement method, and its realization timeline; updated through project execution and handed off at closure
Benefit owners — designated stakeholders (often operations, commercial, or scientific leads — not the project team) who remain accountable for tracking benefits after the project team dissolves
Post-project review checkpoints — scheduled reviews at defined intervals post-closure (e.g., 6 months, 1 year, 2 years) where actual outcomes are compared against business case projections
Transition and readiness requirements — at project close, the PMBOK requires confirming there is a plan to maintain delivered value as the project transitions to operations; this plan should explicitly include BRM handoff protocols
Governance linkage — benefits realization reviews should be embedded in portfolio governance so leadership can use real ROI data to inform future investment decisions
Leading vs. lagging indicators — traditional KPIs can lead to reactive rather than proactive plans; they focus on deliverables, not benefits — a good BRM framework pairs lagging outcome indicators (revenue, approval) with leading process indicators (enrollment rate, site activation time) to give early warning signals
The Organizational Mindset Shift
The dominant project management culture still defines success as "on time, on budget, on scope" — this is necessary but insufficient. The PMBOK explicitly reframes project success around value delivery: "project management activities do not provide value by themselves — they are performed with the intent of delivering and maximizing value." In biotech/pharma, where the gap between project completion and value realization can span years, this mindset shift is not optional — it is a competitive differentiator. A 2022 McKinsey & Company report found that companies that tracked KPIs effectively achieved a 20% higher success rate in launching new drugs compared to their competitors (link). Leadership must sponsor BRM as an organizational practice — not just a PMO exercise — because benefits are realized in operations, commercial, and scientific functions, not within the project itself
Conclusion / Call to Action
Every project in biotech and pharma is an investment thesis — the business case makes the argument, but only post-project measurement can confirm or deny it. Building the KPI framework and benefits tracking infrastructure before a project closes is not extra work — it's how organizations learn whether their decisions were sound. At Ganvion Biotech Solutions, we help clients design benefits realization frameworks tailored to the specific project type, regulatory context, and organizational maturity — so that when a project closes, the story doesn't end there.
